Crown Bioscience announced that it has developed and validated a set of models for immuno-oncology called HuGEMM. The models were developed in partnership with Nanjing Galaxy Biopharmaceutical Co. Ltd.
HuGEMM was developed by directly replacing the murine, or rodent, PD-1 protein with a human counterpart so the model can be used to evaluate human-specific therapeutics for checkpoint inhibitors, including anti-human PD-1, anti-human PDL-1, and anti-human CTLA-4 antibodies. This is necessary because syngeneic mouse tumor models, frequently used for testing surrogate anti-mouse PD-1 antibodies, cannot be models for human-specific therapeutics.
“Up until now, the lack of models available to test the in vivo efficacy of new antibody-based immunotherapies and combination therapies has hindered the research process,” Jean-Pierre Wery, PhD, president of Crown Bioscience, said in a press release. “With HuGEMM™, there is now a robust model system in place to enable scientists to assess the efficacy of human biologic therapeutics directly without resorting to mouse surrogates.”
The validation of HuGEMM was grounded on a study, “Abstract A11: HuGEMM-h/mPD1 mouse models for assessing anti-human PD1 therapeutics,” published in Molecular Cancer Therapeutics, that concluded that chimeric protein human/mouse (h/m) PD1 can interchangeably interact with mPDL1 or hPDL1 as efficiently as mouse PD1, and also recognizes the anti-human PD1 antibody. As such, “the conditioned version 1-HuGEMM-h/mPD1 mouse could be explored to evaluate anti-human antibody activity,” the researchers wrote.
Crown is a fully owned subsidiary of Crown Bioscience International, focused on drug discovery and development, and providing translational platforms for research in oncology and metabolic disease.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?